Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.48 |
| ▸ | THRB | P10828 | 3/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639439 | 0.93 | RORC (0.48) | RORCTHRBLPAR1P2RX7ALDH1A1 | |
| SCHEMBL4604847 | 0.87 | HPGD (0.47) | RORCP2RX7MAPTNPC1RAB9A | |
| SCHEMBL4603118 | 0.87 | MAPT (0.54) | RORCP2RX7MAPTNPC1RAB9A | |
| SCHEMBL4603448 | 0.87 | ALDH1A1 (0.47) | RORCP2RX7MAPTNPC1RAB9A | |
| SCHEMBL4603769 | 0.86 | ALDH1A1 (0.51) | RORCMAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL4603542 | 0.85 | MEN1 (0.53) | RORCMAPTNPC1RAB9AMAPK10 | |
| SCHEMBL4602575 | 0.84 | ALDH1A1 (0.46) | RORCMAPTRAB9AALDH1A1HPGD | |
| SCHEMBL4605577 | 0.83 | KMT2A (0.44) | RORCMAPTALDH1A1GAAHPGD | |
| SCHEMBL2638867 | 0.80 | ALDH1A1 (0.50) | RORCP2RX7NPC1RAB9AALDH1A1 | |
| SCHEMBL4606459 | 0.80 | ALDH1A1 (0.53) | RORCMAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940781-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | claimed |
| WO-2007045573-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | claimed |
| EP-1940781-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7388111-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007045573-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088053-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088053-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, QTRT1, RTF1 | RORC 1541/4885THRB 2986/4885LPAR1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.